Regeneron Pharmaceuticals Inc
NASDAQ:REGN
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
743.35
1 201.76
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Regeneron Pharmaceuticals Inc
Operating Margin
Regeneron Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | US |
| Market Cap | 82.6B USD |
| Operating Margin |
30%
|
| Country | FR |
| Market Cap | 6T USD |
| Operating Margin |
-17 527%
|
| Country | US |
| Market Cap | 314.7B USD |
| Operating Margin |
28%
|
| Country | US |
| Market Cap | 157B USD |
| Operating Margin |
19%
|
| Country | US |
| Market Cap | 115.9B USD |
| Operating Margin |
40%
|
| Country | US |
| Market Cap | 112.2B USD |
| Operating Margin |
38%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Operating Margin |
-370%
|
| Country | AU |
| Market Cap | 133.6B AUD |
| Operating Margin |
26%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Operating Margin |
-33%
|
| Country | NL |
| Market Cap | 34.5B EUR |
| Operating Margin |
-22%
|
| Country | US |
| Market Cap | 31.5B USD |
| Operating Margin |
-9%
|
Regeneron Pharmaceuticals Inc
Glance View
Regeneron Pharmaceuticals Inc., based in Tarrytown, New York, has established itself as a powerhouse in the biopharmaceutical industry, primarily focusing on the development of innovative treatments for serious medical conditions. Founded in 1988, the company has built a robust pipeline of cutting-edge drugs that address a variety of diseases, including eye disorders, cancer, and autoimmune diseases. Regeneron's flagship product, Eylea, has transformed the treatment of retinal diseases, generating significant revenue and proving the company's capability to bring breakthrough therapies to market. The company's strong commitment to research and development is complemented by its proprietary VelociGene and VelociMouse technologies, which facilitate rapid and effective drug discovery. Investors are drawn to Regeneron not only for its impressive product portfolio but also for its strong financial performance and strategic collaborations. The company's unique approach combines scientific rigor with entrepreneurial spirit, allowing it to navigate the complex landscape of pharmaceutical development successfully. Regeneron's partnership with international health organizations during the COVID-19 pandemic, particularly through its antibody treatments, showcased its agility and dedication to public health. With a solid balance sheet and an unwavering focus on innovation, Regeneron Pharmaceuticals stands out as a compelling investment opportunity in the biotechnology sector, poised for continued growth and success in addressing critical healthcare needs.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Regeneron Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 30.3%.
You don't have any saved screeners yet
